Literature DB >> 30904564

Advances and challenges in development of precision psychiatry through clinical metabolomics on mood and psychotic disorders.

Mariana Pedrini1, Bing Cao2, João Victor Silva Nani3, Raphael O Cerqueira4, Rodrigo B Mansur5, Ljubica Tasic6, Mirian A F Hayashi3, Roger S McIntyre5, Elisa Brietzke7.   

Abstract

Metabolomics is defined as the study of the global metabolite profile in a system under a given set of conditions. The objective of this review is to comprehensively assess the literature on metabolomics in mood disorders and schizophrenia and provide data for mental health researchers about the challenges and potentials of metabolomics. The majority of studies in metabolomics in Psychiatry uses peripheral blood or urine. The most widely used analytical techniques in metabolomics research are nuclear magnetic resonance (NMR) and mass spectrometry (MS). They are multiparametric and provide extensive structural and conformational information on multiple chemical classes. NMR is useful in untargeted analysis, which focuses on biosignatures or 'metabolic fingerprints' of illnesses. MS targeted metabolomics approach focuses on the identification and quantification of selected metabolites known to be involved in a particular metabolic pathway. The available studies of metabolomics in Schizophrenia, Bipolar Disorder and Major Depressive Disorder suggest a potential in investigating metabolic pathways involved in these diseases' pathophysiology and response to treatment, as well as its potential in biomarkers identification.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bipolar disorder; Major depressive disorder; Mental disorders; Metabolomics; Personalized treatment; Schizophrenia

Mesh:

Year:  2019        PMID: 30904564     DOI: 10.1016/j.pnpbp.2019.03.010

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  7 in total

1.  LC-MS/MS determination of plasma catecholamines after selective extraction by borated zirconia.

Authors:  Juan Le; Ting Sun; Rui Peng; Teng-Fei Yuan; Yu-Qi Feng; Shao-Ting Wang; Yan Li
Journal:  Mikrochim Acta       Date:  2020-02-12       Impact factor: 5.833

2.  Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression.

Authors:  Siamak MahmoudianDehkordi; Ahmed T Ahmed; Sudeepa Bhattacharyya; Xianlin Han; Rebecca A Baillie; Matthias Arnold; Michelle K Skime; Lisa St John-Williams; M Arthur Moseley; J Will Thompson; Gregory Louie; Patricio Riva-Posse; W Edward Craighead; William McDonald; Ranga Krishnan; A John Rush; Mark A Frye; Boadie W Dunlop; Richard M Weinshilboum; Rima Kaddurah-Daouk
Journal:  Transl Psychiatry       Date:  2021-03-02       Impact factor: 6.222

3.  Searching for biomarkers in schizophrenia and psychosis: Case-control study using capillary electrophoresis and liquid chromatography time-of-flight mass spectrometry and systematic review for biofluid metabolites.

Authors:  Saehyeon Kim; Satoshi Okazaki; Ikuo Otsuka; Yutaka Shinko; Tadasu Horai; Naofumi Shimmyo; Takashi Hirata; Naruhisa Yamaki; Takaki Tanifuji; Shuken Boku; Ichiro Sora; Akitoyo Hishimoto
Journal:  Neuropsychopharmacol Rep       Date:  2021-12-08

4.  NMR Metabolomics in Serum Fingerprinting of Schizophrenia Patients in a Serbian Cohort.

Authors:  Katarina Simić; Nina Todorović; Snežana Trifunović; Zoran Miladinović; Aleksandra Gavrilović; Silvana Jovanović; Nataša Avramović; Dejan Gođevac; Ljubodrag Vujisić; Vele Tešević; Ljubica Tasić; Boris Mandić
Journal:  Metabolites       Date:  2022-07-29

5.  Metabolomic Characterization of Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS).

Authors:  Federica Murgia; Antonella Gagliano; Marcello G Tanca; Noga Or-Geva; Aran Hendren; Sara Carucci; Manuela Pintor; Francesca Cera; Fausto Cossu; Stefano Sotgiu; Luigi Atzori; Alessandro Zuddas
Journal:  Front Neurosci       Date:  2021-05-28       Impact factor: 4.677

6.  A system biology approach based on metabolic biomarkers and protein-protein interactions for identifying pathways underlying schizophrenia and bipolar disorder.

Authors:  Md Altaf-Ul-Amin; Kazuhisa Hirose; João V Nani; Lucas C Porta; Ljubica Tasic; Shaikh Farhad Hossain; Ming Huang; Naoaki Ono; Mirian A F Hayashi; Shigehiko Kanaya
Journal:  Sci Rep       Date:  2021-07-14       Impact factor: 4.379

7.  A metabolome-wide association study in the general population reveals decreased levels of serum laurylcarnitine in people with depression.

Authors:  Helena U Zacharias; Johannes Hertel; Hamimatunnisa Johar; Maik Pietzner; Karoline Lukaschek; Seryan Atasoy; Sonja Kunze; Henry Völzke; Matthias Nauck; Nele Friedrich; Gabi Kastenmüller; Hans J Grabe; Christian Gieger; Jan Krumsiek; Karl-Heinz Ladwig
Journal:  Mol Psychiatry       Date:  2021-06-04       Impact factor: 15.992

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.